ReviewDiseases (Basel, Switzerland)2025
Herpes Zoster: Risk Factors for Occurrence, Complications, and Recurrence with a Focus on Immunocompromised Patients.
Review in Diseases (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Feasibility and safety of recombinant zoster vaccination in patients undergoing active cancer treatments: A real-world single-center experience.Human vaccines & immunotherapeutics · 2026Observational
- Varicella zoster virus infection and reactivation in a psychiatric ward during the COVID-19 pandemic: a case series analysis.Clinical and experimental vaccine research · 2026Article
- Cutaneous-Tropism Viruses: Unraveling Pathogenetic Mechanisms and Immunoprophylactic Strategies.Life (Basel, Switzerland) · 2026Review
- FLARE: A Flow Cytometry-Based Fluorescent Assay for Measuring HSV-1 Nuclear Egress.Bio-protocol · 2026Article
- gE mutations and VZV genotypes jointly predict pain relief outcomes in herpes zoster: an integrative immunologic and modeling study.Frontiers in immunology · 2026Article
- Article
- Development and validation of a machine learning model for predicting postherpetic neuralgia risk.Frontiers in neurology · 2026Article
- Current practices in the diagnosis and management of HSV and CMV reactivation in German ICUs: an exploratory web-based survey.Frontiers in medicine · 2026Article
- Determinants of Hospital Length of Stay in Herpes Zoster Patients: A Four-Year Retrospective Study.Health science reports · 2025Article
- Article
- Varicella-zoster virus infection: a review about varicella and herpes zoster.Anais brasileiros de dermatologiaReview
- The quality and reliability of herpes zoster information on TikTok and Bilibili: A cross-sectional study.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe varicella-zoster virus is a highly contagious human herpesvirus that primarily causes varicella (chickenpox) as an initial infection, targeting T cells, neurons, as well as skin cells, and can later reactivate to cause herpes zoster (shingles). Following reactivation, the varicella-zoster virus infection can lead to severe complications, the most common of which is postherpetic neuralgia. Risk factors include aging, immunosuppression, chronic diseases such as diabetes, cardiovascular disorders, respiratory conditions, and others.
objectiveIn this article, we present an analysis of factors increasing the risk of herpes zoster occurrence, complications, and recurrences (in particular in immunocompromised patients).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.